Abstract 5984
Background
Xerostomia is a common symptom in cancer patients undergoing radiation to the head and neck region and/or those undergoing systemic chemotherapy. Acupuncture has been recognized as an effective integrative modality for managing xerostomia, but data about predicting treatment response to acupuncture are limited. We explored patient characteristics and treatment response among patients who received acupuncture for xerostomia.
Methods
We reviewed acupuncture records with a primary referral for xerostomia in an outpatient environment from March 2016 to April 2018. Treatment response was assessed using Edmonton Symptom Assessment Scale (ESAS; 0-10 scale) performed pre and post each acupuncture treatment. Bivariate associations between patient characteristics and treatment response were analyzed.
Results
A total of 781 acupuncture treatment records (139 patients) were identified. Majority were male (63%) and 59 (42%) with head and neck cancer. The median treatment response was 11% (IQR: 0-33) reduction in xerostomia score. BMI ≥ 35 and Charlson comorbidity index (CCI) <6 were associated with greater symptom reduction: BMI ≥ 35 (17% [IQR: 0%-100%]) vs BMI < 35 (10% [IQR: 0%-33%]), P = 0.012; CCI < 6 (14% [IQR: 0%-33%]) vs CCI ≥ 6 (0% [IQR: 0%-25%]), P = 0.003. Mental wellbeing (PROMIS Mental Health score) (P = 0.024) positively correlated with greater reduction in xerostomia score. High severity of fatigue and sleep problems correlated with less symptom reduction (P = 0.008 and P = 0.006, respectively). Higher blood glucose level was associated with less reduction (P = 0.002) in xerostomia score.
Conclusions
Using the current approach, acute pre-post treatment response of xerostomia to acupuncture was low. Features of patient clinical characteristics may be predictive of treatment response. More research is needed to further explore these associations and examine the impact of optimization of clinical conditions on acupuncture treatment response in symptom management for cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4883 - A New Population Model Validated Pharmacokinetic Similarity of HLX01 and Rituximab in B-Cell Lymphoma
Presenter: Yuankai Shi
Session: Poster Display session 1
Resources:
Abstract
4908 - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Nam Lim
Session: Poster Display session 1
Resources:
Abstract
2360 - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
Presenter: Seok Jae Huh
Session: Poster Display session 1
Resources:
Abstract
2430 - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017
Presenter: Jeong Yeon Kim
Session: Poster Display session 1
Resources:
Abstract
4654 - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients
Presenter: Guldane Cengiz Seval
Session: Poster Display session 1
Resources:
Abstract
1732 - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
5784 - N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
Presenter: Sergey Semochkin
Session: Poster Display session 1
Resources:
Abstract
836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma
Presenter: Ching-Liang Ho
Session: Poster Display session 1
Resources:
Abstract
2085 - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation
Presenter: Hanafy Hafez
Session: Poster Display session 1
Resources:
Abstract
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract